CH676715A5 - - Google Patents

Download PDF

Info

Publication number
CH676715A5
CH676715A5 CH3921/88A CH392188A CH676715A5 CH 676715 A5 CH676715 A5 CH 676715A5 CH 3921/88 A CH3921/88 A CH 3921/88A CH 392188 A CH392188 A CH 392188A CH 676715 A5 CH676715 A5 CH 676715A5
Authority
CH
Switzerland
Prior art keywords
group
mpl
acid
monophosphoryl lipid
hydrogen
Prior art date
Application number
CH3921/88A
Other languages
German (de)
English (en)
Inventor
Kent R Myers
Edgar E Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of CH676715A5 publication Critical patent/CH676715A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CH3921/88A 1987-10-22 1988-10-21 CH676715A5 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/112,742 US4987237A (en) 1983-08-26 1987-10-22 Derivatives of monophosphoryl lipid A

Publications (1)

Publication Number Publication Date
CH676715A5 true CH676715A5 (cg-RX-API-DMAC10.html) 1991-02-28

Family

ID=22345625

Family Applications (1)

Application Number Title Priority Date Filing Date
CH3921/88A CH676715A5 (cg-RX-API-DMAC10.html) 1987-10-22 1988-10-21

Country Status (10)

Country Link
US (1) US4987237A (cg-RX-API-DMAC10.html)
JP (1) JPH075623B2 (cg-RX-API-DMAC10.html)
BE (1) BE1003250A5 (cg-RX-API-DMAC10.html)
CA (1) CA1308711C (cg-RX-API-DMAC10.html)
CH (1) CH676715A5 (cg-RX-API-DMAC10.html)
DE (1) DE3836006C2 (cg-RX-API-DMAC10.html)
FR (1) FR2622192A1 (cg-RX-API-DMAC10.html)
GB (1) GB2211502B (cg-RX-API-DMAC10.html)
IT (1) IT1230592B (cg-RX-API-DMAC10.html)
NL (1) NL8802595A (cg-RX-API-DMAC10.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5498708A (en) * 1989-07-18 1996-03-12 Montefiore Medical Center Method of synthesizing polyesters
KR940004071B1 (ko) * 1990-04-12 1994-05-11 니홍 다바꼬 상교 가부시끼가이샤 4,6-o-히드록시포스포릴글루코사민 유도체
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5164375A (en) * 1991-09-27 1992-11-17 Merck & Company, Inc. Antifungal agent
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP5004261B2 (ja) 2000-05-19 2012-08-22 コリクサ コーポレイション 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
DK1482795T3 (da) * 2002-02-04 2010-02-01 Corixa Corp Nye immuneffektor-forbindelser
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
PL220778B1 (pl) 2002-07-08 2016-01-29 Corixa Corp Sposoby wytwarzania 4-fosforanu aminoalkiloglukozaminidu oraz związki pośrednie
CA2512108C (en) 2003-01-06 2013-04-02 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1449535T3 (da) * 2003-02-18 2006-09-11 Clinique La Prairie Res Sa Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
US20070014795A1 (en) * 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
PT2173376E (pt) * 2007-08-02 2015-07-30 Biondvax Pharmaceuticals Ltd Vacinas de influenza multiepitópicas multiméricas
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN105658661B (zh) 2013-02-20 2020-07-24 卑尔根技术交易股份公司 疫苗
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2019052975A1 (en) 2017-09-13 2019-03-21 Sanofi Pasteur IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
EP3841111A1 (en) 2018-08-24 2021-06-30 Vestlandets Innovasjonsselskap AS Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens
CN115151559A (zh) 2019-10-02 2022-10-04 扬森疫苗与预防公司 葡萄球菌肽和使用方法
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
MX2023008251A (es) 2021-01-12 2023-07-26 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con estos y uso de estos.
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0414725Y2 (cg-RX-API-DMAC10.html) * 1980-09-30 1992-04-02
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS62129293A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 親水性のリピドａ単糖類縁体
JPS62195396A (ja) * 1986-02-20 1987-08-28 Toho Yakuhin Kogyo Kk 親水性及び疎水性の基を置換したりピドａ単糖類縁体

Also Published As

Publication number Publication date
CA1308711C (en) 1992-10-13
IT8822399A0 (it) 1988-10-21
JPH01146891A (ja) 1989-06-08
BE1003250A5 (fr) 1992-02-11
DE3836006A1 (de) 1989-05-03
FR2622192B1 (cg-RX-API-DMAC10.html) 1994-11-10
IT1230592B (it) 1991-10-28
FR2622192A1 (fr) 1989-04-28
NL8802595A (nl) 1989-05-16
JPH075623B2 (ja) 1995-01-25
GB2211502A (en) 1989-07-05
DE3836006C2 (de) 1996-07-11
JPH075623B1 (cg-RX-API-DMAC10.html) 1995-01-25
GB2211502B (en) 1992-02-19
US4987237A (en) 1991-01-22
GB8824330D0 (en) 1988-11-23

Similar Documents

Publication Publication Date Title
CH676715A5 (cg-RX-API-DMAC10.html)
KR860000274B1 (ko) 갱글리오사이드의 분자내 에스테르 유도체의 제조방법
DE2655500C2 (cg-RX-API-DMAC10.html)
EP0519327B1 (de) N-Acyl-S-(2-hydroxyalkyl)-cysteine, deren Herstellung sowie deren Verwendung als Zwischenprodukte zur Herstellung von synthetischen Immunadjuvantien und synthetischen Impfstoffen
DE60023748T2 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DD160417A5 (de) Verfahren zur herstellung von n-(vinblastin-23-oyl)-aminosaeurederivate
DE4115468A1 (de) Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE3887820T2 (de) Antibiotika, Benanomicine A und B und Dexylosylbenanomicin B, ihre Herstellung und Verwendung.
US4304726A (en) Process for the preparation of cholesterol derivatives
DE69033257T2 (de) Zytotoxische zyklische Depsipeptide des Manteltierchen Trididemnum Solidum
EP0658585B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
DE3044740A1 (de) Nucleosidderivate, ihre herstellung und pharmazeutische mittel
EP0060999B1 (de) Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien
DD210687A5 (de) Verfahren zur herstellung von (+)-cyanidan-3-ol-derivaten
DE2557145C3 (de) Tyrosinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69019217T2 (de) Perylenquinon (UCN-1028D)-Derivate.
US4225525A (en) Vitamin D3 metabolite derivatives
EP1603930A1 (de) Proteinbindende derivate von platinkomplexen mit cyclobutan-1,1-dicarboxylatliganden
EP0087751B1 (de) Wasserlösliche Peptide sehr schwer löslicher Aminosäuren
DE68913936T2 (de) Retro-Inverso-Thrymopentin-Analoge, Verfahren zu deren Herstellung und deren Verwendung für die Zubereitung von pharmazeutischen Zusammensetzungen.
DE69017771T2 (de) Thymopentin-Analoge mit allen umgekehrten Verbindungen, Verfahren zur deren Herstellung und deren Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen.
DE2710457A1 (de) 2-(2-acetamido-2-desoxy-3-0-d-glucopyranosyl)-d-propionyl-l-seryl-isoglutamin, 2-(2-acetamido-2-desoxy-3-0- d-glucopyranosyl)-d-propionyl-l-seryl- d-glutaminsaeure, die amid- und ester- derivate dieser verbindungen, verfahren zu ihrer herstellung und diese verbindungen als wirkstoffe enthaltende arzneimittel
DD262998A5 (de) Verfahren zur herstellung eines konjugates von einem vinca-alkaloid mit einem protein
CH628323A5 (de) Verfahren zur herstellung von cholecystokinin-pancreozymin-octapeptidamid-sulfatester.
EP1129107B1 (de) Verfahren zur herstellung von l-prolyl-l-m-sarcolysyl-l-p-fluorphenylalanin und von derivaten davon

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.

Free format text: RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US) -TRANSFERTO- RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US)

PL Patent ceased